Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Jun 19:1-9. doi: 10.3724/zdxbyxb-2023-0585. Online ahead of print.
ABSTRACT
Metabolic syndrome (MS) is a complex group of metabolic disorders with an increasing global incidence rate, posing a serious threat to human health. Currently, there is no specific effective drug for its clinical treatment. Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new class of oral hypoglycemic drugs. They not only promote urinary glucose excretion by inhibiting the reabsorption of glucose by renal proximal convoluted tubule epithelial cells, thereby reducing blood glucose in a non-insulin-dependent manner, but also reduce blood glucose by improving the function of islet β cells, reducing inflammatory responses, and inhibiting oxidative stress. In addition, SGLT2 inhibitors can also reduce body weight through osmotic diuresis and increased fat metabolism; reduce blood pressure by inhibiting excessive activation of sympathetic nervous system and improving vascular function; improve blood lipids by increasing degradation of triglyceride; reduce blood uric acid by promoting uric acid excretion in kidney and intestine and reducing uric acid synthesis. Therefore, this article reviews the improvement effects of SGLT2 inhibitors on multiple metabolic disorders in MS and its related regulatory mechanisms.
PMID:38899358 | DOI:10.3724/zdxbyxb-2023-0585
